Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/068516external-prioritypatent/WO2014037532A1/en
Application filed by H Lundbeck AsfiledCriticalH Lundbeck As
Publication of MA37957A1publicationCriticalpatent/MA37957A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
La présente invention concerne des procédés de traitement de la démence comprenant l'administration d'une dose quotidienne efficace de n-(2-(6-fluoro-1h-indol-3-yl)éthyl-(2,2,3,3-tétrafluoropropoxy)benzylamine pour améliorer ou augmenter l'effet d'un inhibiteur de l'acétylcholinestérase.The present invention relates to methods of treating dementia comprising administering an effective daily dose of n- (2- (6-fluoro-1H-indol-3-yl) ethyl- (2,2,3,3 tetrafluoropropoxy) benzylamine to enhance or enhance the effect of an acetylcholinesterase inhibitor.
MA37957A2012-09-092015-03-30
Methods of treating alzheimer's disease and associated pharmaceutical compositions
MA37957A1
(en)